From GlobeNewswire: 2025-04-15 02:31:00

BioPorto A/S successfully completed a private placement of 25,000,000 new shares, raising a total of 33.5 million DKK. The company plans to use the proceeds to fund new clinical trials for FDA approval of ProNephro AKI™ NGAL for adult use in the US and to further develop their commercial platform. The new shares are expected to be traded on Nasdaq Copenhagen under the company’s permanent ISIN code by April 30, 2025. BioPorto is a diagnostic company focused on early identification and assessment of acute kidney injury, with their NGAL biomarker product leading the way in this field.



Read more at GlobeNewswire: Rettet emission af 25.000.000 nye aktier fuldt